In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas

The majority of patients with relapsed or refractory large B-cell lymphomas (R/R LBCL) treated with CAR-T cell therapy experience disease progression. We previously identified that most relapses include local failures at PET avid sites that were present prior to CAR T cell infusion. We hypothesize that targeting unfavorable lesions with bridging radiation (RT) may prevent local failure.We retrospectively identified R/R LBCL patients treated with...